Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 8, 2015, Pages 1217-1225

  Zhu, Meidong ^a,b   Chew, Jamie K ^a,b   Broadhead, Geoffrey K ^a,b   Luo, Kehui ^c   Joachim, Nichole ^a   Hong, Thomas ^a   Syed, Adil ^a,b   Chang, Andrew A ^a,b  

^a Sydney Institute of Health Sciences   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

As needed treatment model; Exudative age related macular degeneration; Five year treatment; Neovascular age related macular degeneration (nAMD); Ranibizumab; Wet macular degeneration

Indexed keywords

ANTIGLAUCOMA AGENT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ANGINA PECTORIS; ARTICLE; CENTRAL MACULAR THICKNESS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG SAFETY; EPIPHORA; EYE EXAMINATION; EYE PAIN; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; INTRAOCULAR HYPERTENSION; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; SUBRETINAL FLUID; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL ACUITY CHART; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINA; RETROSPECTIVE STUDY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RETINA; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84938348467     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2799-8     Document Type: Article

References (29)

1. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB (2011) Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 129(1):75–80
2. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379(9827):1728–1738
3. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115(1):116–126
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431
5. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116(1):57–65 e55
6. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94(1):2–13
7. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43–58 e41
8. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399–1411
9. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388–1398
10. Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ (2012) Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 96(12):1469–1473
11. Krüger Falk M, Kemp H, Sorensen TL (2013) Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 155(1):89–95 e83
12. Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M, Lund-Andersen H, Sander B (2013) A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology
13. Schachat AP (2013) Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol 156(1):1–2 e1
14. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, Wolf S (2009) Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 50(7):3432–3437
15. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M (2014) Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration. Ophthalmology 121(1):188–192
16. Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh AC, Romano PW, Sadda SR (2007) Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 48(9):4300–4307
17. Krebs I, Hagen S, Smretschnig E, Womastek I, Brannath W, Binder S (2012) Reproducibility of segmentation error correction in age-related macular degeneration: Stratus versus Cirrus OCT. Br J Ophthalmol 96(2):271–275
18. Hatef E, Khwaja A, Rentiya Z, Ibrahim M, Shulman M, Turkcuoglu P, Sepah Y, Wang J, Channa R, Bittencourt M, Akhtar A, Heo J, Do DV, Nguyen QD (2012) Comparison of time domain and spectral domain optical coherence tomography in measurement of macular thickness in macular edema secondary to diabetic retinopathy and retinal vein occlusion. J Ophthalmol 2012:354783
19. Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing snellen visual acuity measurements. Retina 30(7):1046–1050
20. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H (2013) Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina 33(8):1487–1502
21. Golbaz I, Ahlers C, Stock G, Schutze C, Schriefl S, Schlanitz F, Simader C, Prunte C, Schmidt-Erfurth UM (2011) Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 52(3):1599–1605
22. Brown DM, Tuomi L, Shapiro H (2013) Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 33(1):23–34
23. Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group (2014) Comparison of Optical Coherence Tomography Assessments in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology
24. Giani A, Cigada M, Choudhry N, Deiro AP, Oldani M, Pellegrini M, Invernizzi A, Duca P, Miller JW, Staurenghi G (2010) Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 150(6):815–824
25. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908
26. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310
27. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548
28. Abell RG, Kerr NM, Allen P, Vote BJ (2012) Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 96(12):1474–1478
29. Brynskov T, Kemp H, Sorensen TL (2014) No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina 34(5):951–957